-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HocOxxNAI14SyJfUdarJ+iTYbmqgnlIcTiemZZR+yP9R+p7t4l4X7egougu5hDZs yoNR1N7XoYYVNyKXWY3mDQ== 0000916641-00-000248.txt : 20000316 0000916641-00-000248.hdr.sgml : 20000316 ACCESSION NUMBER: 0000916641-00-000248 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000315 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NOVITRON INTERNATIONAL INC CENTRAL INDEX KEY: 0000716646 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 042573920 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-39041 FILM NUMBER: 570268 BUSINESS ADDRESS: STREET 1: ONE GATEWAY CENTER STREET 2: SUITE 411 CITY: NEWTON STATE: MA ZIP: 02158 BUSINESS PHONE: 6172619933 MAIL ADDRESS: STREET 1: ONE GATEWAY CENTER STREET 2: SUITE 411 CITY: NEWTON STATE: MA ZIP: 02158 FORMER COMPANY: FORMER CONFORMED NAME: CLINICAL DATA INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: KIRK RANDAL J CENTRAL INDEX KEY: 0001091823 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: THIRD SECURITY LLC STREET 2: THE GOVERNOR TYLER CITY: RADFORD STATE: VA ZIP: 24141 MAIL ADDRESS: STREET 1: THIRD SECURITY LLC STREET 2: THE GOVERNOR TYLER CITY: RADFORD STATE: VA ZIP: 24141 SC 13D/A 1 CLINICAL CHEMISTRY HOLDINGS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) NOVITRON INTERNATIONAL, INC. ________________________________________________________________________________ (Name of Issuer) COMMON STOCK, $.01 par value share ________________________________________________________________________________ (Title of Class of Securities) 670088103 _______________________________________________________________ (CUSIP Number) Third Security, LLC The Governor Tyler 1902 Downey Street Radford, Virginia 24141 Attention: Marcus E. Smith, Esq. Telephone No.: 540-731-3344 ________________________________________________________________________________ (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: John Owen Gwathmey, Esq. Hunton & Williams Riverfront Plaza, East Tower 951 East Byrd Street Richmond, Virginia 23219 March 10, 2000 _______________________________________________________________ (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [_]. Page 1 of 8 Pages - -------------------------- ----------------------- CUSIP NO. 670088103 SCHEDULE 13D Page 2 of 8 Pages - -------------------------- ----------------------- - ------------------------------------------------------------------------------ NAMES OF REPORTING PERSONS 1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). Randal J. Kirk S.S. No.: ###-##-#### - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 2 (a) [_] (b) [_] - ------------------------------------------------------------------------------ SEC USE ONLY 3 - ------------------------------------------------------------------------------ SOURCE OF FUNDS 4 PF - ------------------------------------------------------------------------------ CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] 5 - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 6 United States - ------------------------------------------------------------------------------ SOLE VOTING POWER 7 NUMBER OF SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 8 OWNED BY 393,333 ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 9 REPORTING PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 10 393,333 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 393,333 - ------------------------------------------------------------------------------ CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 12 [_] - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 27.3% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON 14 IN - ------------------------------------------------------------------------------ - -------------------------- ----------------------- CUSIP NO. 670088103 SCHEDULE 13D Page 3 of 8 Pages - -------------------------- ----------------------- - ------------------------------------------------------------------------------ NAMES OF REPORTING PERSONS 1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). Clinical Chemistry Holdings, Inc. I.R.S. Identification No.: 52-2202556 - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 2 (a) [_] (b) [_] - ------------------------------------------------------------------------------ SEC USE ONLY 3 - ------------------------------------------------------------------------------ SOURCE OF FUNDS 4 WC - ------------------------------------------------------------------------------ CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [_] 5 - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 6 Delaware - ------------------------------------------------------------------------------ SOLE VOTING POWER 7 NUMBER OF SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 8 OWNED BY 393,333 ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 9 REPORTING PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 10 393,333 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 393,333 - ------------------------------------------------------------------------------ CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 12 [_] - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 27.3% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON 14 CO - ------------------------------------------------------------------------------ This Amendment No. 1 (the "Amendment") amends and supplements the Statement on Schedule 13D, dated November 26, 1999 and filed on December 6, 1999 (the "Original Schedule 13D"), relating to the Common Stock, par value $.01 per share (the "Common Stock"), of Novitron International, Inc., a Delaware corporation (the "Issuer"). Mr. Randal J. Kirk and Clinical Chemistry Holdings, Inc., a Delaware corporation that is controlled by Mr. Kirk ("CCH" and, together with Mr. Kirk, the "Reporting Persons"), are filing this Amendment to update the information in the Original Schedule 13D with respect to the beneficial ownership of the Common Stock by the Reporting Persons. Item 3. Source and Amount of Funds or Other Consideration. -------------------------------------------------- Item 3 of the Original Schedule 13D is hereby amended and supplemented as follows: "During the period commencing February 2, 2000 and ending March 14, 2000, CCH used approximately $84,076 of working capital to purchase 32,100 shares of Common Stock and sold 10,000 shares of Common Stock for approximately $20,644." Item 5. Interest in Securities of the Issuer. ------------------------------------- Item 5(a) of the Original Schedule 13D is hereby amended to read in its entirety as follows: "The aggregate number and percentage of shares of Common Stock to which this statement relates is 393,333 shares, representing 27.3% of the 1,441,925 shares outstanding as reported by the Issuer on February 8, 2000 in the Issuer's Quarterly Report on Form 10-Q for the quarter ended December 31, 1999 (the most recent available filing by the Issuer with the Securities and Exchange Commission). CCH beneficially owns all of the shares to which this statement relates, and Mr. Kirk is deemed to have beneficial ownership of the shares owned by CCH." Item 5(c) of the Original Schedule 13D is hereby amended and supplemented as follows: "The following table lists all transactions in shares of Common Stock by the Reporting Persons that were effected from December 6, 1999, the date on which this Statement on Schedule 13D was originally filed with the Securities and Exchange Commission, through March 14, 2000:
Shares Purchased Average Price Reporting Person Date (Sold) Per Share** - -------------------------------------------------------------------------------------------- CCH 2/2/00 2,400 $1.94 CCH 2/3/00 1,000 $1.94 CCH 2/4/00 1,500 $1.97 CCH 2/18/00 1,000 $3.00 CCH 2/22/00 1,000 $3.00 CCH 2/23/00 1,800 $3.00 CCH 2/28/00 2,000 $3.00
Page 4 of 8 Pages Shares Purchased Average Price Reporting Person Date (Sold) Per Share** - -------------------------------------------------------------------------------------------- CCH 3/6/00 1,500 $3.00 CCH 3/9/00 1,500 $2.88 CCH 3/10/00 4,000 $2.75 CCH 3/13/00 7,000 $2.41 CCH 3/13/00 (10,000) $2.06 CCH 3/14/00 7,400 $2.77
* Unless otherwise indicated, all transactions were effected on the Nasdaq. ** Price excludes commission." Item 7 Material to be Filed as Exhibits. --------------------------------- The following document is being filed as an exhibit to this Amendment and is incorporated herein by reference: Exhibit 7. Joint Filing Agreement. Page 5 of 8 Pages SIGNATURE --------- After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Date: March 15, 2000 /s/ Randal J. Kirk ------------------------------- Randal J. Kirk Date: March 15, 2000 CLINICAL CHEMISTRY HOLDINGS, INC. By: /s/ Audrey Ho Ping Ting ----------------------- Audrey Ho Ping Ting President and Chief Executive Officer Page 6 of 8 Pages EXHIBIT INDEX ------------- Exhibit Number Exhibit - -------------- ------- Exhibit 7. Joint Filing Agreement. Page 7 of 8 Pages Exhibit 7 --------- JOINT FILING AGREEMENT ---------------------- In accordance with Rule 13d-1(f) promulgated under the Securities Exchange Act of 1934, as amended, the persons names below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Novitron International, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this agreement as of the 6th day of December, 1999. Date: December 6, 1999 /s/ Randal J. Kirk ----------------------------------------- Randal J. Kirk Date: December 6, 1999 CLINICAL CHEMISTRY HOLDINGS, INC. By: /s/ Audrey Ho Ping Ting ----------------------- Audrey Ho Ping Ting President and Chief Executive Officer Pages 8 of 8 Pages -----END PRIVACY-ENHANCED MESSAGE-----